What is it about?
We suggest that JME patients can effectively be treated with single low VPA dose (500mg daily),while at the same time seizure precipitating factors, such as sleep deprivation and alcohol ingestion, should be avoided.
Featured Image
Why is it important?
Juvenile myoclonic epilepsy is a syndrome that has only recently attracted considerable attention. Remarkably, JME is often diagnosed with delay because the physicians involved, including the specialists, are not familiar with a disease whose nature has yet to unfold. JME is believed to be a lifelong epilepsy; this view however, has been debated from time to time. The duration of treatment has not been established yet. We suggest that it appears safe and effective to initiate treatment of JME with a single low VPA dose (500 mg daily), while at the same time seizure precipitating factors, such as sleep deprivation and alcohol ingestion, should be avoided.
Perspectives
It remains to be elucidated if all JME patients can safely be treated with initiation of a low dose VPA and if not, which are the characteristics in their medical profile that may reduce the effectiveness of initiation with low dose VPA treatment
Professor Stavros J Baloyannis or Balogiannis or Balojannis or Baloyiannis or Mpalogiannis
Aristotle University of Thessaloniki
Read the Original
This page is a summary of: Low dose sodium valproate in the treatment of juvenile myoclonic epilepsy, Journal of Neurology, April 2002, Springer Science + Business Media,
DOI: 10.1007/s004150200028.
You can read the full text:
Contributors
The following have contributed to this page
